Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CDR404 |
| Synonyms | |
| Therapy Description |
CDR404 is a bispecific T-cell engager that targets MAGE-A4, which potentially leads to increased immune cell activation, killing of tumor cells expressing MAGE-A4, and decreased tumor growth (Journal for ImmunoTherapy of Cancer 2023;11). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CDR404 | CDR-404|CDR 404 | CDR404 is a bispecific T-cell engager that targets MAGE-A4, which potentially leads to increased immune cell activation, killing of tumor cells expressing MAGE-A4, and decreased tumor growth (Journal for ImmunoTherapy of Cancer 2023;11). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06402201 | Phase I | CDR404 | First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors | Recruiting | USA | ITA | ESP | DNK | BEL | 0 |